Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...

Goiter

Goiter

Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...

The Thyroid Gland

The Thyroid Gland

The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tailored Vein Sampling and Surgery in Primary Aldosteronism.

JAMA surgery·2026

Same author

Molecular pathology of primary aldosteronism and hypercortisolism: Impact on adrenal surgery.

iScience·2026

Same author

Preventing Cushing Syndrome: Adrenalectomy in <i>PDE11A</i>-Positive Primary Pigmented Nodular Adrenocortical Disease.

JCEM case reports·2026

Same author

Massive Pheochromocytomatosis Treated With Cytoreductive Surgery.

JCEM case reports·2026

Same author

Primary aldosteronism: adrenalectomy could save more lives.

Frontiers in endocrinology·2025

Same author

Mild Autonomous Cortisol Secretion in Congenital Adrenal Hyperplasia Managed With Mini Back Scope Adrenalectomy.

JCEM case reports·2025

Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026

Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026

Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026

Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026

Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026

Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 5, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Thyroid cancer.

Tobias Carling¹, Robert Udelsman

¹Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06510; email: Tobias.carling@yale.edu ; Robert.udelsman@yale.edu.

Annual Review of Medicine

|November 27, 2013

Summary

This summary is machine-generated.

Thyroid cancer incidence is rising, but mortality is stable, prompting debate on early detection and treatment. Surgical extent and radioactive iodine use also remain controversial topics in thyroid cancer management.

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Experiment Videos

Last Updated: May 5, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Area of Science:

Oncology
Endocrinology

Background:

Thyroid cancer incidence is increasing globally.
Mortality rates for thyroid cancer have remained stable.
This discrepancy raises questions about current diagnostic and treatment paradigms.

Purpose of the Study:

To review the current controversies in thyroid cancer diagnosis and management.
To discuss the role of molecular analysis in thyroid cancer.

Main Methods:

Literature review of recent studies on thyroid cancer.
Analysis of current debates regarding surgical extent and radioactive iodine therapy.
Evaluation of the utility of molecular diagnostics and targeted therapies.

Main Results:

Thyroid cancer's favorable natural history challenges the need for early detection and aggressive treatment in all cases.
Controversies exist regarding the optimal surgical approach (partial vs. total thyroidectomy) and lymph node dissection.
The precise role and dosage of radioactive iodine therapy require further clarification.
Molecular analysis is increasingly important for diagnosis and identifying therapeutic targets.

Conclusions:

The management of thyroid cancer requires careful consideration of individual patient factors and tumor characteristics.
Ongoing research into molecular pathways is crucial for developing targeted therapies for advanced disease.
Further consensus is needed on surgical extent and adjuvant therapies to optimize patient outcomes.